Onc Nurse On Call is the new podcast by Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, AOCN, and ...

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk ...

The FDA has greenlit niraparib and abiraterone acetate (AAP; Akeega) with prednisone for the treatment of adults with deleterious or suspected deleterious BRCA2 -mutated metastatic hormone-sensitive ...

The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of ...

Combining azacitidine with venetoclax (Venclexta) significantly increased event-free survival (EFS) vs intensive induction ...

The FDA has approved the use of lisocabtagene maraleucel in patients with relapsed/refractory marginal zone lymphoma. The FDA has approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the ...

Blinatumomab/ponatinib increased efficacy and response rates were improved in patients with Philadelphia-positive acute lymphoblastic leukemia.

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.

A 30-year retrospective analysis of clinical trials involving patients with acute myeloid leukemia (AML) receiving intensive chemotherapy demonstrated that Black race is an independent prognostic ...

The addition of epcoritamab to R2 significantly reduced the risk of death or disease progression in patients with relapsed/refractory follicular lymphoma.